Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine

Silvia Nastasio, Marco Sciveres, Lorenza Matarazzo, Cristina Malaventura, Francesco Cirillo, Silvia Riva, Giuseppe Maggiore

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Cyclosporine (CSA) is an alternative treatment for autoimmune hepatitis (AIH), however, its unknown long-term safety and efficacy have limited its use. Aims: Examine the long-term outcome of children and young adults with AIH treated with CSA for at least 4 years. Methods: Twenty patients were included in this retrospective study: 15 with classical AIH and 5 with autoimmune hepatitis/autoimmune sclerosing cholangitis overlap syndrome (ASC). CSA was administered as first (12 patients) or second-line (8 patients) treatment, alone or in combination with azathioprine or mycophenolate mofetil and/or prednisone. Results: CSA determined initial clinical and biochemical remission in all patients. At the end of follow-up (median 8.6; range 4–20.4 years), all patients are alive with their native liver; 15 in complete remission (75%), 2 with incomplete response to treatment and 3 listed for liver transplant. Side effects were mild and transitory after dose tapering or, in 1 case, after CSA withdrawal. Hypertrichosis and moderate gingival hyperplasia were the most frequent. Two patients presented mild transient glomerular filtration rate (GFR) reduction. Median GFR at the beginning and end of treatment was not statistically different for all patients. Conclusions: CSA was effective and safe in the long-term treatment of our cohort of patients with AIH, tailoring the treatment remains key-points during CSA administration.

Original languageEnglish
JournalDigestive and Liver Disease
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Autoimmune Hepatitis
Cyclosporine
Young Adult
Glomerular Filtration Rate
Therapeutics
Gingival Hyperplasia
Hypertrichosis
Mycophenolic Acid
Sclerosing Cholangitis
Liver
Azathioprine
Prednisone
Retrospective Studies
Transplants
Safety

Keywords

  • Autoimmune hepatitis
  • Autoimmune sclerosing cholangitis
  • Cyclosporine
  • Glomerular filtration rate
  • Overlap syndrome

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine. / Nastasio, Silvia; Sciveres, Marco; Matarazzo, Lorenza; Malaventura, Cristina; Cirillo, Francesco; Riva, Silvia; Maggiore, Giuseppe.

In: Digestive and Liver Disease, 01.01.2018.

Research output: Contribution to journalArticle

Nastasio, Silvia ; Sciveres, Marco ; Matarazzo, Lorenza ; Malaventura, Cristina ; Cirillo, Francesco ; Riva, Silvia ; Maggiore, Giuseppe. / Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine. In: Digestive and Liver Disease. 2018.
@article{e2f3ba53a1a0467a828d7723ff7eeff3,
title = "Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine",
abstract = "Background: Cyclosporine (CSA) is an alternative treatment for autoimmune hepatitis (AIH), however, its unknown long-term safety and efficacy have limited its use. Aims: Examine the long-term outcome of children and young adults with AIH treated with CSA for at least 4 years. Methods: Twenty patients were included in this retrospective study: 15 with classical AIH and 5 with autoimmune hepatitis/autoimmune sclerosing cholangitis overlap syndrome (ASC). CSA was administered as first (12 patients) or second-line (8 patients) treatment, alone or in combination with azathioprine or mycophenolate mofetil and/or prednisone. Results: CSA determined initial clinical and biochemical remission in all patients. At the end of follow-up (median 8.6; range 4–20.4 years), all patients are alive with their native liver; 15 in complete remission (75{\%}), 2 with incomplete response to treatment and 3 listed for liver transplant. Side effects were mild and transitory after dose tapering or, in 1 case, after CSA withdrawal. Hypertrichosis and moderate gingival hyperplasia were the most frequent. Two patients presented mild transient glomerular filtration rate (GFR) reduction. Median GFR at the beginning and end of treatment was not statistically different for all patients. Conclusions: CSA was effective and safe in the long-term treatment of our cohort of patients with AIH, tailoring the treatment remains key-points during CSA administration.",
keywords = "Autoimmune hepatitis, Autoimmune sclerosing cholangitis, Cyclosporine, Glomerular filtration rate, Overlap syndrome",
author = "Silvia Nastasio and Marco Sciveres and Lorenza Matarazzo and Cristina Malaventura and Francesco Cirillo and Silvia Riva and Giuseppe Maggiore",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.dld.2018.10.018",
language = "English",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine

AU - Nastasio, Silvia

AU - Sciveres, Marco

AU - Matarazzo, Lorenza

AU - Malaventura, Cristina

AU - Cirillo, Francesco

AU - Riva, Silvia

AU - Maggiore, Giuseppe

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Cyclosporine (CSA) is an alternative treatment for autoimmune hepatitis (AIH), however, its unknown long-term safety and efficacy have limited its use. Aims: Examine the long-term outcome of children and young adults with AIH treated with CSA for at least 4 years. Methods: Twenty patients were included in this retrospective study: 15 with classical AIH and 5 with autoimmune hepatitis/autoimmune sclerosing cholangitis overlap syndrome (ASC). CSA was administered as first (12 patients) or second-line (8 patients) treatment, alone or in combination with azathioprine or mycophenolate mofetil and/or prednisone. Results: CSA determined initial clinical and biochemical remission in all patients. At the end of follow-up (median 8.6; range 4–20.4 years), all patients are alive with their native liver; 15 in complete remission (75%), 2 with incomplete response to treatment and 3 listed for liver transplant. Side effects were mild and transitory after dose tapering or, in 1 case, after CSA withdrawal. Hypertrichosis and moderate gingival hyperplasia were the most frequent. Two patients presented mild transient glomerular filtration rate (GFR) reduction. Median GFR at the beginning and end of treatment was not statistically different for all patients. Conclusions: CSA was effective and safe in the long-term treatment of our cohort of patients with AIH, tailoring the treatment remains key-points during CSA administration.

AB - Background: Cyclosporine (CSA) is an alternative treatment for autoimmune hepatitis (AIH), however, its unknown long-term safety and efficacy have limited its use. Aims: Examine the long-term outcome of children and young adults with AIH treated with CSA for at least 4 years. Methods: Twenty patients were included in this retrospective study: 15 with classical AIH and 5 with autoimmune hepatitis/autoimmune sclerosing cholangitis overlap syndrome (ASC). CSA was administered as first (12 patients) or second-line (8 patients) treatment, alone or in combination with azathioprine or mycophenolate mofetil and/or prednisone. Results: CSA determined initial clinical and biochemical remission in all patients. At the end of follow-up (median 8.6; range 4–20.4 years), all patients are alive with their native liver; 15 in complete remission (75%), 2 with incomplete response to treatment and 3 listed for liver transplant. Side effects were mild and transitory after dose tapering or, in 1 case, after CSA withdrawal. Hypertrichosis and moderate gingival hyperplasia were the most frequent. Two patients presented mild transient glomerular filtration rate (GFR) reduction. Median GFR at the beginning and end of treatment was not statistically different for all patients. Conclusions: CSA was effective and safe in the long-term treatment of our cohort of patients with AIH, tailoring the treatment remains key-points during CSA administration.

KW - Autoimmune hepatitis

KW - Autoimmune sclerosing cholangitis

KW - Cyclosporine

KW - Glomerular filtration rate

KW - Overlap syndrome

UR - http://www.scopus.com/inward/record.url?scp=85057228837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057228837&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2018.10.018

DO - 10.1016/j.dld.2018.10.018

M3 - Article

AN - SCOPUS:85057228837

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

ER -